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Background: Treatment disengagement and non-completion poses a major problem for the successful treatment
of patients with severe mental illness. Motivation for treatment has long been proposed as a major determinant of
treatment engagement, but exact mechanisms remain unclear. This current study serves three purposes: 1) to
determine whether a feedback intervention based on the patients’ motivation for treatment is effective at
improving treatment engagement (TE) of severe mentally ill patients in outpatient psychiatric treatment, 2) to
gather insight into motivational processes and possible mechanisms regarding treatment motivation (TM) and TE in
this patient population and 3) to determine which of three theories of motivation is most plausible for the
dynamics of TM and TE in this population.
Methods/design: The Motivation and Treatment Engagement Intervention Trial (MotivaTe-IT) is a multi-center
cluster randomized trial investigating the effectiveness of feedback generated by clinicians regarding their patients’
treatment motivation upon the patients’ TE. The primary outcome is the patients’ TE. Secondary outcomes are TM,
psychosocial functioning and quality of life. Patients whose clinicians generate monthly motivation feedback
(additional to treatment as usual) will be compared to patients who receive treatment as usual. An estimated 350
patients, aged 18 to 65 years, with psychotic disorders and/or severe personality disorders will be recruited from
outpatient community mental health care. The randomization will be performed by a computerized randomization
program, with an allocation ratio of 1:1 (team vs. team or clinician vs. clinician) and patients, but not clinicians, will
be blind to treatment allocation at baseline assessment. Due to the nature of the trial, follow-up assessment can
not be blinded.
Discussion: The current study can provide important insights regarding motivational processes and the way in
which motivation influences the treatment engagement and clinical outcomes. The identification of possible
mechanisms through which changes in the outcomes occur, offers a tool for the development of more effective
future interventions to improve TM and TE.
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Disengagement and non-completion of treatment pose a
major problem for the successful treatment of patients
with severe mental illness, since it is associated with
several clinical and socio-economical problems such
as recurrent psychiatric problems, rehospitalisation, and
increased risk of suicide and episodes of violence [1-3].
Estimates of treatment disengagement vary across differ-
ent psychiatric patient populations and depend on the
definitions of disengagement and non-completion. For
example, non-adherence to antipsychotic medication
among patients with psychotic disorders was observed
in over 50% of patients [4,5], while non-completion of
personality disorder treatment is estimated at 37% [6].
Lehner et al. [3] found that among individuals in treat-
ment for severe mental illness, appointment failures ran-
ged from 50% to 73%, drop-out estimates ranged from
14% to 92% and medication failure estimates ranged
from 5% to 71%.
Research into the determinants of treatment engage-
ment and completion of treatment in severe mental ill-
ness has revealed numerous important factors, including
patient-related factors (e.g. age, ethnicity, beliefs about
treatment efficacy, income level, psychiatric history),
illness-related factors (e.g. the type of disorder, symptom
severity, comorbidity) and treatment-related factors (e.g.
treatment setting, type of treatment, treatment efficacy,
adverse treatment effects, therapeutic alliance) [2,7-9].
Although some of these factors are static and can not be
influenced, others are more dynamic and may therefore
be targeted in interventions to enhance treatment en-
gagement. One dynamic factor that has long been recog-
nized as an important determinant of treatment
engagement is the patient’s motivation to make the
efforts required by the treatment [9-12]. However, due
to an abundance of conceptualizations of the global term
‘motivation’, it has proven difficult for both academics
and clinicians to effectively work with the concept. As
Drieschner et al. [12] point out, despite a large amount
of publications regarding treatment motivation, the con-
cept remains ill-defined and is therefore a continued
source of confusion. Therefore, more insight into the
associations between determinants of motivation, actual
motivation to engage in treatment, treatment engage-
ment and psychosocial functioning may contribute to
the effectiveness of psychiatric interventions.
This article describes the study protocol for the Motiv-
ation and Treatment Engagement Intervention Trial
(MotivaTe-IT). MotivaTe-IT serves two purposes: 1) to
determine whether a feedback intervention based on the
patients’ motivation for treatment is effective at improv-
ing treatment engagement (TE) of severe mentally ill
patients in outpatient psychiatric treatment, and 2) to
gather insight into motivational processes and possiblemechanisms regarding motivation for treatment and
treatment engagement in this patient population. In the
following, we will describe why we chose to use motiv-
ation feedback as the intervention in this study.
Motivation feedback intervention
Studies employing feedback to clinicians have shown
that monitoring and informing clinicians of their
patients’ treatment progress in psychotherapy is effective
in enhancing retention and outcome [13-18]. Providing
systematic feedback can be seen as an addition to regu-
lar treatment and may guide changes, prolongation or
termination of treatment. It ensures that the attempts to
resolve the problems can be evaluated, and if necessary,
adjusted [19]. In several studies by Lambert et al.
[13,14,16] in a psychotherapy setting, progress feedback
was based upon four domains of functioning, including
psychological disturbance (mainly depression and anx-
iety), interpersonal problems, social role functioning and
quality of life [17]. The effects of feedback were most
pronounced in patients who showed a poor initial re-
sponse to treatment [15]. Feedback is also increasingly
being researched in other settings. In a study in patients
with psychotic disorders in a community mental health
setting, patients were asked to rate their quality of life
and satisfaction with treatment, which was fed back to
clinicians and discussed [20].When compared to control
patients (who did not make use of feedback) after
12 months, patients in the feedback condition reported
better quality of life, fewer unmet care needs and higher
satisfaction with treatment. However, the groups showed
no statistically significant difference on psychopathology
scores (i.e. positive, negative or general symptoms of
schizophrenia). In another study conducted among SMI
patients receiving community care, where clinicians
received feedback on their patients’ care needs, a signifi-
cant improvement was found in patient satisfaction, but
not on psychopathology, social functioning and quality
of life [21] when compared to controls. A study con-
ducted in the Netherlands among patients with severe
mental illness, found that systematic monitoring of
patients’ care needs in combination with feedback
provision was associated with global improvement in de-
pression and anxiety symptoms, but not with improve-
ment in manic excitement and positive symptoms [22].
It seems that structured feedback has positive effects on
some central outcomes of community mental health care
(e.g. quality of life and patient satisfaction) but not on
others (e.g. level of symptoms or functioning), depending
on the setting and the content of the feedback.
In a study by Whipple et al. [16] a more extensive form
of feedback was used when compared to the Lambert
et al. studies [13,14], where the authors found that using
clinical support tools (CSTs) additional to feedback upon
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longer, and that these clients were twice as likely to
show superior outcomes. These CSTs incorporated mea-
sures to assess the therapeutic relationship, the motiv-
ation to change and the social support network. These
results line up with other studies about feedback to clini-
cians and point out that the use of support tools is of
additional value [16]. However, a limitation of Whipple’s
study was that it was not possible to determine the
effects of the individual components (e.g. motivation to
change) in the CSTs upon outcome. Some studies have
compared the effects of personalized feedback with the
effects of motivational interviewing including persona-
lized feedback, and found that feedback only is less ef-
fective than motivational interviewing with feedback in
achieving behaviour change [23-25]. Therefore, next to
providing feedback, it seems important to apply add-
itional strategies in order to improve the motivation of
patients to engage in treatment.
The aforementioned clinician feedback research has
focused primarily upon treatment progress and was un-
able to determine which specific element(s) from the
clinical support tools provided the mechanism(s) of ac-
tion. Since treatment motivation has been found to be of
crucial importance in this matter [9-12], the current
study set out to place treatment motivation in a central
position. The feedback that will be provided to the clini-
cians in the current study revolves around the patients’
motivation to engage in their treatment. Therefore, our
feedback intervention is labelled motivation feedback.
The feedback to clinicians will be based upon the
current motivational state of their patients regarding
their motivation for remaining and engaging in
treatment.
Furthermore, solely providing feedback to clinicians of
patients with severe mental illness might not be suffi-
ciently intensive to improve treatment engagement [16].
To aid clinicians in addressing motivational problems
that become evident from the feedback, clinicians will
be educated in motivation enhancement strategies based
on Self-Determination Theory [26,27]. Despite the dif-
ferences between the Transtheoretical Model [28], the
Integral Model of Treatment Motivation [12], and Self-
Determination Theory [26] on the concept of treatment
motivation, these theories may complement each other
[29]. A detailed discussion of similarities and differences
in how these three theories predict treatment engage-
ment and outcomes can be found in Jochems et al. [29].
We chose Self-Determination Theory (SDT) [27] as
the basis of our motivation feedback intervention, since
this theory encompasses both a qualitative and quantita-
tive view of motivation and the intervention strategy
that it implies seems suitable for patients with SMI.
In brief, SDT postulates different types of motivation,where the most central distinction is made between
autonomous (i.e. self-determined) motivation and con-
trolled (i.e. externally determined) motivation. Autono-
mous motivation may vary from intrinsic motivation to
types of extrinsic motivation in which people have iden-
tified with the value of a change and have integrated
this change into their sense of self [30]. SDT poses that
autonomously motivated people experience greater
ownership of the behaviour, will have greater intention
to persist in treatment and have better mental health
outcomes [30,31]. In contrast, controlled motivation
consists of external regulation, in which behaviour is
regulated by external rewards or punishments, and
introjected regulation, where the drive for behaviour is
partially internalised and energised by avoidance of
shame, guilt and anxiety [27]. When people have a con-
trolled motivation, they will show poorer health out-
comes according to theory [30]. Furthermore, SDT states
that fulfilling the patients’ basic psychological needs of
autonomy, competence and relatedness during treatment
will facilitate internalization of motivation for treatment,
leading to better health outcomes [30].
Methods/design
Aims
The study has three main objectives. The primary
objective is to determine the effects of the motivation
feedback intervention on treatment engagement (TE) of
patients with psychotic and/or personality disorders.
Secondary outcomes are the patient’s treatment motiv-
ation, psychosocial functioning and quality of life. To
this end, clinicians will be randomly assigned to either of
two groups; one group will generate SDT-based feedback
on the motivation of their patients while the other group
will not.
The second objective is to determine the factors asso-
ciated with the effect of our motivation feedback inter-
vention upon the primary and secondary outcomes.
Several demographic and clinical factors as well as fac-
tors that have a theory-based and/or empirically estab-
lished relationship with the outcomes will therefore be
assessed. At the moment, it is unclear which exact fac-
tors are most important so this will be studied
explorative.
The third and final objective of the study is to deter-
mine which theory of motivation is most plausible
for the dynamics of TE and treatment motivation in
patients with psychotic disorders and personality disor-
ders in outpatient treatment. The models selected here
are the Transtheoretical Model (TTM) [28], the Integral
model of treatment motivation (IM) [12] and Self-
Determination Theory (SDT) [27]. In a literature review
that we have performed earlier, we have described
these theories in detail, including their differences and
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(i.e. TTM, SDT, and IM) is most supported by the data
in predicting treatment motivation and engagement. It is
possible that different subcomponents of these theories
will be integrated in a novel theoretical-empirical model
tailored to this specific population.
Hypotheses
It is hypothesized that motivation feedback to clinicians
on the treatment motivation of their patients will lead to
an increase in both the quantity and quality of treatment
motivation and treatment engagement of these patients.
The patient’s self-reported motivation and the clinician-
reported motivation of the patient are expected to in-
duce more awareness regarding motivational issues that
are at play during treatment, and subsequently to more
suitable (motivational) interventions leading to better
outcomes (i.e. treatment engagement and psychosocial
functioning). More specifically, we expect the increase in
quantity and quality of motivation will follow the pat-
terns shown in Figure 1. For example, in the interven-
tion group we expect a larger increase in autonomousFigure 1 Visualization of the three motivation theories and their inte
POC1: Processes of change (consciousness raising, dramatic relief); POC2: P
(self-liberation); POC4: Processes of change (reinforcement management, h
S: Self-efficacy; DB: Decisional Balance; SDT: Self Determination Theory.motivation (concept from SDT), a larger proportion of
patients making forward shifts in the stages of change
(concept from TTM) and a larger increase in motivation
to engage in treatment (concept from IM) relative to
the control group. As a consequence, we expect the
intervention group to show a higher level of treatment
engagement than the control group at the time of follow-
up, as demonstrated by higher clinician-rated treatment
engagement, less no-shows and better antipsychotic medi-
cation adherence in the patients with psychotic disorders.
Treatment groups
Control condition: treatment as usual
The control condition consists of patients who are pro-
vided treatment as usual (TAU). These patients receive
care that is guided by their individual symptoms, pro-
blems and needs. Treatment may consist of assertive
outreach, medication, cognitive (behavioural) therapy,
stress-management, family therapy, and/or supportive
structured therapy. Assertive outreach is provided by
Flexible Assertive Community Treatment (FACT) teams.
FACT is a team treatment model that aims to providerrelations. IM: Integral Model; TTM: TransTheoretical Model;
rocesses of change (self-reevaluation); POC3: Processes of change
elping relationships, counterconditioning, stimulus control);
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psychiatric services to individuals with SMI [32,33].
Besides assertive outreach, which is the key feature of
Assertive Community Treatment (ACT), there is an
emphasis on out-of-office interventions and home visits,
but when patients constitute a danger to themselves or
others and are not motivated for treatment, clinicians
can start a procedure for them to be committed to a
psychiatric hospital [33]. During hospitalisations, the
ACT team keeps into contact with the patient to secure
continuity of care. In the Netherlands, a special type
of ACT teams exist, called Flexible-ACT (FACT).
Van Veldhuizen (2007) has described Dutch FACT as
follows: “FACT is a rehabilitation-oriented clinical case
management model, which is based on the ACT model
but is more flexible and able to serve a broader range of
clients with severe mental illness. FACT offers the ori-
ginal ACT as one of several treatment or care models.
The FACT team is a case management team with partly
an individual approach and partly a team approach; the
approach varies from patient to patient, depending on
the patient’s needs. For more stable long-term patients
FACT provides coordinated multidisciplinary treatment
and care by individual case management. Unstable
patients at risk of relapse, neglect and readmission are
provided with intensive assertive outreach care by the
same team, working with a shared caseload for this sub-
group. (p.422)” Patients and clinicians in the TAU condi-
tion will be assessed at baseline and at 12 months
follow-up. Type, duration and frequency of TAU will
be monitored.Intervention condition: motivation feedback
Patients randomized to the motivation feedback condi-
tion will receive treatment as usual (TAU) and addition-
ally, their clinicians will generate information regarding
the patient’s motivation to engage in treatment. Patients
and clinicians in the intervention group will fill in a
short motivation feedback questionnaire every month
up to twelve months after baseline assessment that
provides the clinicians with motivation feedback. The
short motivation feedback questionnaire includes eight
statements that relate to the level and type of the
patient’s treatment motivation, based on two types of
motivation as distinguished by SDT. The individual
items of both clinician and patients are rated on a 10-
point continuous scale and can be plotted against each
other in a graph to represent visual motivation feedback
to the clinician. This graph then shows both the patient’s
rating and the clinician’s rating of the current level of
autonomous and controlled motivation of the patient.
Figure 2 presents a hypothetical motivation profile and
graphs of a possible course of the motivation over time.Previous pilot testing with the short motivation feed-
back questionnaire among 55 patients with primarily
anxiety and depressive symptoms receiving outpatient
treatment showed that the list was comprehensible and
easy to use in clinical practice. Clinicians appreciated the
brevity and clarity of the items, which could function as a
starting point for the discussion with the patient regard-
ing his/her current motivation to engage in treatment.
Clinicians will be asked to fill in the short motivation
feedback questionnaire just before the appointment with
the patient. After having filled in the questions, the clin-
ician will ask the patient at the beginning of the appoint-
ment to also fill in the questions on motivation for
treatment. This information will be used by the clinician
as a starting point for the discussion with the patient
regarding his/her motivation for treatment. Clinicians
randomized to the feedback condition, are expected to
measure and discuss the current motivational status of
their patients monthly. The clinician may use the infor-
mation from the questionnaire and the subsequent con-
versation with the patient about this as feedback and
apply an intervention tailored to the patients’ current
motivation. Clinicians will be free to decide for them-
selves how they will structure this discussion with the
patient (e.g. discuss only one item or several, discuss dif-
ferences between patient and clinician vision) and how
long this will take. In case the patient is unable or un-
willing to indicate his/her motivation, the clinician may
still use his own judgment of the motivation of the pa-
tient and use this as self-generated feedback. Addition-
ally, the motivation of the clinician to keep treating the
particular patient is also measured monthly by asking
the clinician to rate two other motivation items.
Before commencing the study, clinicians will be
trained by the principal investigator how to read and in-
terpret the motivation feedback graphs. During this
training, they are given a presentation about the princi-
ples of Self Determination Theory, the different types of
motivation postulated by SDT and perform exercises to
learn how to distinguish the needs for autonomy, com-
petence and relatedness in discussions with the patient.
Clinicians also perform feedback assessments on each
other during this training, to familiarize themselves with
the feedback and how to introduce it to their patients.
During the course of the study (i.e. one year) clinicians
will be regularly contacted by the principal investigator
to evaluate the motivation feedback intervention and to
discuss their progress and experiences together with
other colleagues who also participate in the motivation
feedback intervention. During the evaluation sessions
with the principal investigator, it can be checked
whether the feedback is still being used properly (and if
not, actions can be taken). To aid clinicians in remem-
bering to perform SMFL assessments monthly, they will
Figure 2 Hypothetical motivation feedback: the motivation profile by the clinician and patient (top parts) and the course of
motivation (bottom graphs). The top part shows that although the clinician and patient agree that the patient is currently in treatment to
solve problems and aim for a better life, the patient indicates that he also finds it important to feel proud of himself and to not disappoint
himself. This could be a starting point for the discussion. In the lower graphs, it can be seen that the autonomous motivation had risen in the
first three measurements and then dropped in the subsequent two measurements, at which point the clinician might choose to intervene.
Jochems et al. BMC Psychiatry 2012, 12:209 Page 6 of 17
http://www.biomedcentral.com/1471-244X/12/209be given MotivaTe-IT bookmarks to use in their paper
planners, electronic reminders will regularly be placed in
the electronic planners, and the principal investigator
will send emails to remind the clinicians of the motiv-
ation feedback.
In case a patient is transferred to another clinician
during the course of the study (e.g. in case of treatment
by a FACT-team where several clinicians cooperate to
provide services to patients), the feedback generated by
the patient will be provided to the clinician who is cur-
rently the primary clinician (i.e. case-manager) involved
with the patient. The feedback generated by clinicians
who have been engaged with the patient at an earlier
moment in time will be provided to the clinician who is
currently the primary clinician, so that it remains pos-
sible to keep monitoring the development of the
patient’s motivation over time.
Development of the motivation feedback intervention
The guidance provided by the UK’s Medical Research
Council on developing and evaluating complexinterventions (www.mrc.ac.uk/complexinterventionsgui-
dance) states that the identification of evidence base and
theory, the modelling of process and outcomes, assessing
feasibility and piloting methods are important steps to-
wards successful evaluations of complex interventions.
The motivation feedback intervention under study here,
although new in it’s emphasis on motivation for treat-
ment as the content of feedback (as opposed to care
needs or quality of life), is otherwise fairly similar to pre-
viously trialled clinician feedback where it was found that
feedback improved SMI patient outcomes in community
mental health settings [20-22]. As Self-Determination
Theory is the theoretical basis for the intervention, this
ensures that the effects (or potentially no effects) of the
intervention can be viewed in light of the processes of
change proposed by this theory. Pilot testing with the
novel short motivation feedback questionnaire in a group
of patients with depressive and anxiety disorders showed
that the list was comprehensible and easy to use, for
both patients and clinicians. The clinicians reported that
the questionnaire gave rise to interesting discussions
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ician was unaware of, such as partners or children being
more important drives to remain in treatment than levels
of distress, or patients expressing that they felt very
much coerced to enter treatment at first (sometimes
even traumatic) but felt that this had progressed to more
internal drives during the course of treatment. These
pilot evaluations strengthened our belief that the inter-
vention could be executed as intended. Due to time lim-
itations however, no piloting was done with patients with
SMI and the psychometric properties of this question-
naire remain to be determined. These issues will there-
fore be addressed during the course of the trial.
Design and setting
This study is a multicenter randomized controlled study
with two treatment conditions: treatment as usual
(TAU) and motivation feedback (additional to TAU).
There will be two extensive measurement occasions for
both groups: at baseline and follow-up at 12 months.
Twelve departments within the Mental Health Center
West North Brabant (MHC WNB), and the Mental
Health Center BreBurg (MHC Breburg) located in the
south west of the Netherlands, were approached to par-
ticipate in the study. The MHC WNB and MHC Bre-
burg provide mental health care to varying patient
populations, including patients with a primary diagnosis
of psychotic and/or personality disorder who will be tar-
geted for this study. The current study will take place at
several treatment locations of the MHC WNB and MHC
Breburg, and represents a partnership between these
centers and the Epidemiological and Social Psychiatric
Research institute (a research center within the Erasmus
Medical Center in Rotterdam, the Netherlands).
Study population: inclusion and exclusion criteria
The current study aimed for patients with severe mental
illness treated in outpatient community mental health
care, and although there are several definitions of severe
mental illness, most definitions include a diagnosis of se-
vere psychiatric disorder, a treatment duration or illness
duration of at least two years and several disabilities
[34,35]. Since patients with psychotic disorders consti-
tute the majority of patients treated in assertive commu-
nity mental health teams in the Netherlands [33,36] and
patients with severe personality disorders constitute an-
other significant part of the caseload, combined with
clinical observations that these two diagnostic groups
may especially benefit from interventions aimed at im-
proving treatment motivation and treatment engage-
ment, it was decided to incorporate both patient groups
into the study.
The research participants will consist of patients with
a primary diagnosis of a psychotic disorder and/or apersonality disorder, and their clinicians. Patients are eli-
gible for participation if they are aged between 18 and
65 years old and receive individual outpatient treatment
for their psychotic and/or personality disorder. Exclusion
criteria are insufficient command of the Dutch language
and/or a documented diagnosis of organic psychosyn-
drome (e.g. dementia or chronic toxic encephalopathy).
Clinicians will be eligible for participation if they are
the primary health care practitioner involved with the
patient, meaning that he/she is the one that has the
most frequent contacts with this patient. It is expected
that the resulting group of clinicians will mainly consist
of specialized social workers, specialized psychiatric
nurses and psychologists with relevant treatment experi-
ence with this patient population.
Methods
In order to test the three motivational theories while
also trying to limit the level of response burden for study
participants in our intervention trial, proper choices for
instruments had to be made. To ensure that we measure
constructs appropriately for each theory, we tried to stay
as close as possible to the original measures used by
Ryan and Deci [27] for SDT, Prochaska and DiClemente
[37] for TTM and Drieschner et al.[38] for IM. Priority
was given to readily available Dutch versions of meas-
urement instruments, but in case these were not avail-
able we chose to apply a translation procedure to the
original English versions. Since our motivation feedback
intervention is based on SDT, the primary outcome ana-
lysis is focused on this theory. Subsequently we will in-
vestigate how well the other two theories explain the
effects of the intervention. Table 1 gives an overview of
the instruments – questionnaires and interviews – that
will be applied at baseline, monthly (for the intervention
condition only) and at 12 months follow-up to patients
and clinicians. It is estimated that the total duration of
the assessment for clinicians takes 25 minutes per meas-
urement occasion, while for patients this is 70 minutes.
Primary and secondary outcomes
The primary outcome in this study is actual treatment
engagement, as measured with the Service Engagement
Scale (see paragraph on treatment engagement). Second-
ary outcomes in this study are treatment motivation, as
measured with the Treatment Entry Questionnaire (see
paragraph on SDT instruments), administrative data on
missed appointments (see paragraph on treatment en-
gagement), psychosocial functioning and quality of life
(see paragraph on secondary outcomes).
Treatment engagement
Treatment engagement will be measured with the Ser-
vice Engagement Scale (SES) that was constructed by
Table 1 Instruments used at two research contacts and
monthly
Patients
T0 (Baseline) Monthly T1 (12 months)
TMS-f x x
URICA-D x x
SoC Algorithm x x
PCS x
TEQ x x
HCCQ x x
IS x x
Zoo Map test x x
HAQ x x
TCI x
MMAS x x
Stigma Scale x x
HoNOS* x x
BPRS* x x
MANSA* x x
SDT graph** x
Therapists
TMS-f x x
URICA-D x x
SoC Algorithm x x
HAQ x x
SES x x
SDT graph** x
Therapist motivation*** x
* These measures are part of ROM as standard clinical practice, and are thus of
no additional burden to the patient.
** Only patients and therapists in the motivation feedback condition fill in the
SDT graph.
*** Only therapists in the motivation feedback condition fill in two items
regarding their motivation to treat the patient.
TMS-f: Treatment Motivation Scale for forensic patients, URICA-D: University
of Rhode Island Change Assessment – Dutch version, SoC algorithm: Stages
of Change algorithm, PCS: Processes of Change Scale, TEQ: Treatment Entry
Questionnaire, HCCQ: Health Care Climate Questionnaire, IS: Insight Scale,
HAQ: Helping Alliance Questionnaire, TCI: Temperament and Character
Inventory, MMAS: Morisky Medication Adherence Scale, HoNOS: Health of
the Nations Outcome Scale, BPRS: Brief Psychiatric Rating Scale, MANSA:
Manchester Short Assessment of Quality of Life, SDT graph: Self-Determination
graph, SES: Service Engagement Scale.
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that are rated on a 4-point scale ranging from 0 (not at
all) to 3 (most of the time). The four subscales refer to
availability, collaboration, help seeking and treatment
engagement. The scale will be administered to clinicians.
The original English version of the SES has shown good
psychometric properties [39]. As a more objective meas-
ure of treatment engagement, data from the patients’
files will be collected on the frequency of missedappointments with the main clinician, percentage of
missed appointments over all appointments in the past
year, reasons for discontinuation of care or drop-out (if
applicable) and the number of admissions in the past
year (voluntary and involuntary).
Furthermore, the Morisky Medication Adherence
Scale (MMAS) [40] will be administered to only to
patients with psychotic disorders to measure the level of
antipsychotic medication adherence. The MMAS is a
self-report scale that consists of 8 items asking about a
specific medication-taking behaviour. The total scale
score can range from 0 to 8, which will be discretized
into high adherence (score of 8), medium adherence
(score of 6 or 7) or low adherence (score below 6) [40].
The scale was found reliable (Cronbach’s α= 0.83) as a
measure for blood pressure medication adherence in
patients with hypertension [40] and has been adjusted to
fit our study population of psychotic patients. Addition-
ally, the psychiatrists of the patients with psychotic dis-
orders will be asked every six months to indicate
whether they believe the patient adheres to the anti-
psychotic medication and if not, to give reasons for the
patient’s nonadherence.
SDT instruments
The types of motivation that are distinguished by SDT
will be measured with the Treatment Entry Question-
naire (TEQ) [10,41]. It was shown that the TEQ was reli-
able (i.e. internally consistent) for external (Cronbach’s
α = .89), introjected (Cronbach’s α = .89) and identified
motivation (Cronbach’s α = .85) [41]. To our knowledge,
the TEQ has not been studied in a Dutch population be-
fore. Therefore, we translated the original TEQ by Wild
et al. [41] and adapted the wording to fit a population of
patients with severe mental illness in psychiatric treat-
ment (e.g. words that referred specifically to addiction
treatment were replaced by words that reflected more
general treatment by a mental health center). Two trans-
lators performed independent forward translations of
the original TEQ into Dutch and adapted the wording to
fit its application to outpatient psychiatric treatment. A
consensus version was established, consisting of 27 items
that can be rated on a 7-point Likert-scale ranging from
1 (strongly disagree) to 7 (strongly agree). The psycho-
metric properties of this Dutch TEQ are to be investi-
gated in this study.
The Health Care Climate Questionnaire (HCCQ) will
be used to measure the degree to which clinicians are
perceived to be autonomy supportive. Items are scored
on a Likert scale, ranging from 1 (strongly disagree) to 7
(strongly agree). The HCCQ has 15 items that have been
used in studies of weight loss [42] (Cronbach’s α =.92)
and smoking cessation [43] (Cronbach’s α = .96). Appli-
cation of a Dutch HCCQ is not known to us. Therefore,
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dependent translators who subsequently established a
consensus version. This consensus version was back
translated into English by two independent expert trans-
lators to check for discrepancies between the original
version and the backtranslation. On the basis of consen-
sus between all translators, the final Dutch questionnaire
was achieved. The psychometric properties of the Dutch
HCCQ will be determined in this study.
TTM instruments
The stages of change will be measured by staging
algorithms and the University of Rhode Island Change
Assessment – Dutch version (URICA-D). Algorithms
are capable of placing individuals in one of five stages
and have been used extensively in diverse populations
and research areas [37,44,45]. The algorithm approach
involves several questions that ask about attempts and
intentions to change behaviour within certain time
frames corresponding to a particular stage. Both patients
and clinicians will be asked to judge whether the patient
is currently in the precontemplation, contemplation,
preparation, action or maintenance stage with regard to
the patients’ motivation to change his psychiatric pro-
blems and specific problem behaviours if relevant (e.g.
alcohol abuse, drug abuse and criminal behaviours). Pre-
contemplation is defined as ‘not planning to work on my
problems in the next six months’. Contemplation is
defined as ‘planning to work on my problems within the
next six months, but not within 30 days from now’.
Preparation is defined as ‘planning to work actively on
my problems within the next 30 days’. Action is defined
as ‘having worked on my problems actively for the last
30 days, but no longer than six months’. Maintenance is
defined as ‘having worked actively on my problems for
the last six months’. These definitions are similar to
other stage algorithms from TTM [46].
The URICA-D is the Dutch version of the URICA
[47], which is a self-report scale that asks the patient to
first enter a problem and then to indicate on a five point
Likert scale (1 = strongly disagree to 5 = strongly agree)
how much he agrees with a particular statement. The
URICA-D consists of four subscales which represent
four stages of change: precontemplation, contemplation,
action and maintenance. The reliabilities (i.e. Cronbach’s
alpha) for the subscales have been found to range from
0.84 to 0.95 [48].
The processes of change will be measured by asking
patients to indicate how often they make use of the
strategies described in 20 statements, where each
process of change is represented by two statements. The
statements are rated on a five point Likert scale, ranging
from 1 (never) to 5 (repeatedly), consistent with other
measures of the processes of change in TTM [49-51].Application of the processes of change scale in a Dutch
psychiatric patient population is not known to us.
Therefore, we developed a questionnaire based on the
original English questionnaire by Prochaska et al. [50]
and adapted it to a population of people with mental ill-
ness in psychiatric treatment. Two translators performed
independent forward translations of the Processes of
Change Scale (PCS) [50] into Dutch and adapted the
wording to fit its application to change processes in psy-
chiatric treatment. From the 40 items generated in this
translation procedure, a consensus version was estab-
lished from which 20 items were chosen (two items per
process) as most relevant to create a short form of the
processes of change inventory, consistent with other
short forms of the processes of change inventory (e.g. in
the studies of [49,52]). The psychometric properties of
our scale are to be investigated in this study.
The decisional balance constructs and self-efficacy
constructs are incorporated in the Treatment Motivation
Scale for forensic patients [38], a scale that will be used
to measure the constructs of the IM (see next section).
IM instruments
The constructs within the IM will be measured by
the Treatment Motivation Scale for forensic patients
(TMS-f) [38]. The TMS-f consists of eight subscales,
one scale for the motivation to engage in treatment
(MET) and six scales for variables that are summarized
as Internal Determinants of MET: problem recognition,
distress, perceived legal pressure, perceived costs of
treatment, perceived suitability of treatment and out-
come expectancy. An additional scale assesses the
patients’ tendency to respond according to social desir-
ability. The items within the scale of ‘perceived legal
pressure’ were adapted to fit a more broadly defined
concept of perceived External Pressure, in order to fit all
patients in our research population.
The TMS-f has a patient version (85 items) and a clin-
ician version (7 items), and both will be used in our
study. The TMS-f has been found to be a reliable and
valid operationalisation of the constructs in IM
[38,53,54]. However, the TMS-f has only been used in a
forensic psychiatric setting and it remains to be deter-
mined whether the scale is also applicable outside this
setting. In the total patient population in which the scale
was validated, it was found that 61% of the patients had
axis-I disorders, while strong characteristics of personal-
ity disorders were prevalent in 78% of patients [53,55].
The composite reliability of the scale ranges between
α = .83 and α = .91 [38].
Psychosocial functioning
Psychosocial functioning will be measured with the
Dutch version of the Health of the Nations Outcome
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via a semi-structured interview with the patient. The
HoNOS quantifies health and social problems during
the previous two weeks and contains 12 items that refer
to behavioural problems, impairment, symptoms, alcohol
and drug abuse, and social (dis)functioning. Three
HoNOS addendum items are also administered. These
refer to manic symptoms, treatment motivation and
compliance with medication. The items are rated from 0
(no problem) to 4 (very severe problem). The HoNOS
has shown to be reliable and sensitive to change [57]. In
order to obtain a more differentiated understanding of
the psychotic symptoms, five items from the Brief Psy-
chiatric Rating Scale [58] will be administered addition-
ally to the HoNOS items in the interview with the
patient. These include suspiciousness, unusual thought
content, grandiosity, hallucinations and blunted affect.
The BPRS has been used in various settings and has
shown good psychometric properties [59].
Quality of life
The Manchester Short Assessment of Quality of Life
(MANSA) [60] will be used to measure quality of life.
The MANSA is a self-report questionnaire administered
to the patient to measure how satisfied the patient is in
the following life domains: living situation, social rela-
tionships, physical health, mental health, safety, financial
situation, work situation and life as a whole. Each ques-
tion is answered on a 7-point scale (1 = not satisfied, 7 =
very satisfied) and a composite (mean) score is calcu-
lated. The psychometric properties are satisfactory [60],
and the scale has also been validated in a population of
patients with severe mental illness [61].
Covariables
Socio- demographic factors of patients and clinicians
Socio-demographic data on gender, age, ethnicity, mari-
tal status, living situation, housing, distance from the
treatment location, educational background, income,
treatment history, treatment duration, no-shows in
the treatment in the previous twelve months, legal status,
medication use, and DSM-IV diagnosis will be collected
at baseline from the patient’s medical record. In case of
missing information in the medical record, the patient
will be asked to provide the information. Information on
clinician sex, age, years of clinical working experience,
and treatment team was collected from clinicians.
Insight into illness
Impaired insight has been associated with reduced treat-
ment engagement and increased symptoms, as well as
higher rates of involuntary detention [62]. The Insight
Scale [63] will be used to measure a patients’ insight into
illness. This 8-item self-report scale produces a totalscore that ranges between 0 and 12. It was found to be a
reliable, valid and easily applicable measure [63].
Executive functions
There is considerable evidence for cognitive dysfunction-
ing, especially impaired executive functioning, in
patients with severe mental illness [64-66]. Executive
dysfunctioning has been found to contribute to poor
insight in psychosis and might be related to poor treat-
ment engagement [66]. As a measure for executive func-
tions, planning ability was chosen. Although the
Wisconsin Card Sorting Test (WCST; [67]) is typically
administered as a measure for executive functioning
[66], the inclusion of this test to our study instruments
would increase the burden to the patients such that we
decided it was unsuitable for administration. Alterna-
tively, planning ability will be measured with the Zoo
Map test, a subtest of the Behavioural Assessment of Ex-
ecutive Functioning (BADS) [68,69]. The Zoo Map test
asks the patient to draw a route on a map of a zoo and
to visit specific sites in the zoo while applying specific
rules (e.g. ‘you can use the dotted pathways as often as
you want, but the white pathways only once’). There are
two subtests within the Zoo Map test: the first is un-
structured, forcing the patient to plan his route inde-
pendently. This indicates the extent to which the patient
is capable of spontaneous planning. The second condi-
tion is structured and indicates a specific order in which
the patient should visit the specific sites. This indicates
the ability of a patient to follow a concrete, externally
demanded strategy. Theoretically, it is expected that
patients who find it difficult to develop logical strategies
on the Zoo map test also have more difficulties with fol-
lowing a (complex) treatment regimen. The time used
for planning and execution of the task and the number
of mistakes (breaking a rule) are scored, and a profile
score ranging from 0 to 4 for each subtest is then
derived. The BADS has shown adequate validity and
test-retest stability [69,70].
Therapeutic alliance
The therapeutic relationship is measured with the Help-
ing Alliance Questionnaire (HAQ). The Dutch version
of the HAQ comprises 11 items that are rated on a 5-
point scale (completely disagree, disagree, neither agree
nor disagree, agree, completely agree) [71]. Both a pa-
tient and a clinician version have been developed (ex-
ample items include “I feel the clinician understands
me”; “I understand the patient”). The HAQ contains two
scales: Cooperation (Cronbach’s α = 0.88) and Helpful-
ness (Cronbach’s α = 0.76) [71]. Modest associations
have been found between the therapeutic alliance and
client outcomes in community mental health for patients
with severe mental illness [72,73]. However, it has been
Figure 3 Flowchart of MotivaTe-IT procedures.
Jochems et al. BMC Psychiatry 2012, 12:209 Page 11 of 17
http://www.biomedcentral.com/1471-244X/12/209noted that most studies performed in these settings have
been limited by a lack of power and standardized mea-
sures [72]. Possibly, the current study can improve on
these limitations.
Experienced stigma
Stigma will be measured using the 12-item ‘perceived
devaluation and discrimination’ subscale of the self-
report Stigma-Scale [74]. This subscale refers to the per-
ception of common opinions about psychiatric patients,
such as ‘Most people stay friends with someone who has
had a mental illness’ and ‘Most people look down on
people who have been hospitalized for mental illness’.
The items are scored on a scale from 1 (strongly dis-
agree) to 4 (strongly agree). A higher total scale score
means more perceived stigmatization. The scale had ac-
ceptable reliability (Cronbach’s alpha = .78) and con-
struct validity was demonstrated in studies predicting
associations between stigma (as measured with the sub-
scale of ‘perceived devaluation and discrimination’) and
self-esteem, employment, demoralization, quality of life
and treatment seeking in patients with mental illness
[75,76].
Personality characteristics
The temperament dimensions from the Temperament
and Character Inventory (TCI) [77,78] will be used to
measure personality characteristics, in order to explore
the relationship between temperament and motivation
to engage in treatment. The temperament dimensions
from Cloninger’s theory called novelty seeking, harm
avoidance, persistence and reward dependence [78,79]
are used in this study. Convergent validity exists in
the form of studies comparing the TCI scales with
other similar scales of validated personality tests [78].
The internal consistencies (i.e. Cronbach’s alphas) of
the novelty seeking, harm avoidance, persistence and
reward dependence subscales varied between α =0.62
and α =0.90 in psychiatric patients recruited from com-
munity mental health care [78]. The temperament
dimensions are measured by items that can be scored as
true or false.
Procedures and randomization
Figure 3 shows the study procedures. Eligible clinicians
and patients will mainly be approached via specific treat-
ment programs that provide FACT (for a description of
FACT see the section on Treatment As Usual). Clini-
cians who are willing to cooperate in this study will be
informed by the principal investigator regarding the
goals and procedures of the study and receive an infor-
mation brochure. Two weeks after having received the
information brochure, clinicians will be contacted to ask
for participation and to sign informed consent.After having received informed consent from the
clinicians, randomization will be performed at either
clinician-level or team-level. Where clinicians work in
FACT-teams, randomization will be performed at team-
level so that a whole team (all clinicians working in this
team) will be allocated to either the TAU condition or
motivation feedback condition. As teams often work
with a shared caseload between clinicians in the same
team, this decision was made in order to prevent pos-
sible cross-over of the feedback-condition to the TAU
condition within teams. Where clinicians work in an
outpatient clinic on a one-to-one basis (individual case-
management) then randomization will be performed
at the clinician-level. The allocation ratio is 1:1 (i.e. ther-
apist vs. therapist and team vs. team, respectively).
Stratification for diagnosis in advance was considered
unrealistic and impractical, as we would then have to
achieve equal numbers of each patient diagnosis in each
treatment condition, while our randomization is at
team-level and clinician-level. Therefore, we chose to
use multivariate modelling with diagnosis as a covariate
(see section 2.9 ‘Statistical analyses’). Randomisation will
be performed by assigning each randomization unit (e.g.
a team or a clinician) a unique number, which is entered
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randomization.com) that randomizes each unit to a sin-
gle treatment by using randomly permuted blocks. The
randomization is single-blind, as both the principal in-
vestigator and clinicians need to know which condition
the clinicians are in, in order for the clinicians to receive
the necessary training for the intervention condition (or
not). As a consequence, only patients will be blind to
treatment allocation at baseline assessment, while clini-
cians are not. Due to the nature of the trial, follow-up
assessment can not be blinded.
Subsequently, clinicians are asked to provide a list of
their entire caseload to the principal investigator (PI).
The PI will remove patients from this list who do not
fulfil the inclusion criteria or fulfil the exclusion criteria
and subsqequently, the PI will randomly select 10 eli-
gible patients from this list to be asked for participation
in the study. Clinicians will inform their selected
patients about the objectives of the study, and provide a
full explanation of all procedures for the study. If
patients are willing to participate, an appointment is
scheduled for the administration of the HoNOS.
At the beginning of the appointment, again all proce-
dures of the research study are explained to the patient
and signed informed consent will be obtained by the re-
search assistant. Written information will also be pro-
vided to the patient, which explains the nature of the
intervention and provides contact details of the research
team. Following the informed consent procedure, base-
line assessment will take place.
The HoNOS will be administered by the case-manager
of the patient accompanied by an independent research
assistant, who will assist in the interview and scoring of
the HoNOS. This decision was made for several reasons.
The first is that the case-managers have been trained to
administer the HoNOS for Routine Outcome Monitor-
ing, which is primarily used in clinical practice to guide
treatment plans and evaluations and is now secondary
used as an outcome in the current research study. Com-
bining the two approaches ensures that Routine Out-
come Monitoring procedures can be maintained (by the
case-manager) while research requirements can be met
(by the independent research assistant monitoring the
administration and scoring of the HoNOS). Secondly,
the response rate for the interviews is expected to be
higher if the patient is approached by a familiar person
(the case-manager). This might typically be the case for
the more paranoid or anxious patients. Third, the pres-
ence of an independent research assistant who is also
trained in the administration of the HoNOS likely
ensures that the HoNOS is scored appropriately, to
minimise a possible bias that might occur if the case-
manager alone would do this. The self-report question-
naires will be administered by research assistants, onlysometimes in the presence of the case-manager when
the patient is seen at home to ensure the safety of the
research assistant or to minimise feelings of anxiety with
patients (who might feel intimidated by an unfamiliar
person), but always ensuring the confidentiality and ano-
nymity of the collected data.
Assessments of the HoNOS and self-report question-
naires will take place at baseline and follow-up at 12
months. Baseline assessment will take place after
randomization to reduce the variation in the time be-
tween baseline assessment and the start of the interven-
tion. Measuring baseline status close to the start of the
intervention ensures that the information obtained at
baseline assessment is still up to date at the start of the
intervention. A limitation to this approach is that clini-
cians are aware of the treatment allocation, which may
bias their responses. This possible information bias can
not be eliminated since clinicians in the motivation feed-
back condition have to be trained in the relevant proce-
dures before baseline assessment, since shortly after they
will start employing the feedback intervention. Patients
however, will not be informed about their treatment al-
location at baseline assessment and are therefore blind
to treatment allocation at the start of the study. In case
patients drop-out from treatment or complete their
treatment before these 12 months have passed, informa-
tion regarding the reason for ending the treatment and
total treatment duration will be obtained.
Sample size and power calculations
The RCT was designed to enroll an average of 6 patients
for each of 56 participating clinicians. The sample size
was calculated on the basis of our primary hypothesis,
that the intervention group (motivation feedback) would
be more effective than the control group (treatment as
usual) in enhancing treatment engagement, as measured
with the Service Engagement Scale (primary outcome) at
12 months after baseline assessment. The difference be-
tween the motivation feedback group and control group
for the primary outcome is based on a power of 0.80
and an alpha of 0.05 (two-tailed). Earlier studies regard-
ing differences between feedback and treatment as usual
(control) conditions have shown effect sizes (standar-
dized mean differences) ranging from 0.34 to 0.92
[16,17], but were based on treatment progress and not
(solely) on treatment motivation. One RCT studying the
effects of treatment adherence therapy in patients with
psychotic disorders used the SES as outcome measure
and found an effect size of 0.39 [80]. Therefore, we ex-
pect an effect size of approximately 0.40. Using an un-
paired t-test statistic, this resulted in a minimum of 123
subjects per condition. However, as patients are clus-
tered within clinicians, and clinicians are clustered in
teams, the patient and clinician observations can not be
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size was therefore adjusted by the (variance inflation)
factor f = 1 + (m – 1)ρ, to account for the variance that
would have been achieved had there been no clustering.
The cluster size (m) is 6 (patients per clinician) and the
within-cluster correlation (ρ) was estimated from a pre-
vious study to be around 0.07 [21]. Thus, the computed
sample size was inflated by 1.35 to be at least 166 sub-
jects per condition (minimally 332 in total). The SES is
rated by clinicians and so we expect minimal loss to
follow-up on the primary outcome, but to be on the safe
side we will aim for 350 patients as the total sample size.
Statistical analyses
The data of the RCT will be analyzed according to the
intention-to-treat principle. Baseline comparability be-
tween the intervention group and control group in
demographic and clinical variables will be evaluated with
independent samples t-tests and chi-square tests. Fur-
thermore, non-responders (i.e. eligible patients who
chose not to participate in the study) will be compared
to responders with respect to background demographic
and clinical variables with independent samples t-tests
and chi-square tests. Logistic regression analysis will be
applied to test for differences between the motivation
feedback and control group with respect to the primary
and secondary outcomes that are dichotomous variables,
while (multiple) linear regression analysis will be used in
case of continuous outcome variables. For individual cat-
egorical outcome variables, the effectiveness will be
determined by odds ratios, including p-values (two-
tailed). The effectiveness of the variables combined will
be determined by ROC-curves (for categorical out-
comes) and the individual odds ratios, R2 and the indi-
vidual regression coefficients (for continuous outcomes).
The Hosmer and Lemeshow goodness-of-fit test will be
used in case of logistic regression. In case of multiple re-
gression analysis the classical regression diagnostics will
be applied for normality, (non)linearity, heteroscedasti-
city, (influential) outliers and interaction. A subgroup
analysis will be performed for patients with psychotic
disorders for the effects of the intervention upon their
antipsychotic medication adherence. The analyses will
be performed both unadjusted and adjusted for baseline
differences of the distributions between the two treat-
ment groups. In analyzing a specific outcome variable,
the baseline score of that variable will be used as covari-
ate. The analysis will be extended using multilevel ana-
lyses that takes the nesting of measurements into
account. A clustering of outcomes is likely since a single
clinician may treat several patients, and clinicians are
clustered into teams. Multilevel modelling will be per-
formed to check for any clustering effects on the pri-
mary outcome. In the multilevel analyses we considerthe two measurements as the first level and the patient
as the second level. We will explore whether the differ-
ent treatment locations (FACT teams) and institutions
(MHC Breburg and MHC WNB) can be considered as
random factors in the modeling. We will identify pre-
dictive factors in estimating the outcome and whether
there are predictive factors dependent on the type of
treatment condition (interaction between baseline vari-
ables and treatment effect). Furthermore, we will take
into account to what extent patients were exposed to
the intervention by analyzing the dose-effect relation-
ship. We expect (as is the case in most empirical studies
in a psychiatric setting) that missing data will occur. We
expect that the data will be Missing At Random (MAR),
which is allowed to be a function of the observed vari-
ables (both covariates and outcome variables). If the as-
sumption of MAR is violated, the pattern mixture model
approach will be applied. In case predictor variables are
missing, the method of multiple imputations or the
maximum likelihood estimation method will be applied.
For monthly measurements (i.e. the motivation feed-
back graph for patient and therapist, and the therapist
motivation) the method of mixed modelling will be ap-
plied. This highly flexible method enables two level
models: repeated measurements (level 1) and patient
level (level 2).
The three motivational theories will be modelled with
Structural Equation Modelling (SEM), in order to study
their fit to the empirical data, their predictive power and
parsimony (i.e. whether the model can be simplified
without substantially reducing the model fit and predict-
ive power). The three motivational theories will be stud-
ied exploratively to determine which theoretical
constructs are most plausible (i.e. clinically relevant and
statistically significant) for the prediction of the outcome
variables. The difference of the two -2log-likelihood tests
(including the difference of degrees of freedom) will be
used for testing differences between nested models, and
information criteria will be used for differences between
non-nested models (i.e. Akaike Information Criterion/
AIC, Bayesian Information Criterion/BIC and adapted
BIC). Where relevant, the 95% confidence intervals and/
or P-values (two-tailed) will be reported.
Ethical considerations
The current research protocol was endorsed by the
Medical Ethical Committee for Mental Health Care
Institutions (METiGG) and by the committees for scien-
tific research within the two mental health institutions
where the data will be collected (MHC WNB and MHC
Breburg). The collected data are treated according to the
Medical Confidentiality Rules, and are kept in locked
files cabinets. Every patient will be assigned a patient
number, so that processing of the data will occur
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the research group and the medical ethical committee
(METiGG). The study will be conducted in accordance
with the Helsinki Declaration. As mentioned previously,
written informed consent will be obtained for all clini-
cians and patients that are entered into the study.
Patients and clinicians are free to refuse participation at
any time during the research period, without having to
disclose any reason why.
Patients that are included in the study will receive an
incentive of € 15, - after every completion of an exten-
sive measurement (baseline and follow-up). Thus, if a
patient has completed both measurement occasions, he
or she will have received € 30, - in appreciation of his/
her cooperation. These incentives are introduced in
order to increase the response rate, since it is expected
that in this patient population with severe mental illness
and possibly with motivational problems, the response
rate would otherwise turn out too low. The effects of the
intervention are unknown at this moment, and therefore
we think it is justified to allocate patients randomly over
the two conditions.
Discussion
The central research question in this study is whether
the motivation feedback intervention is able to increase
the treatment engagement of patients in outpatient psy-
chiatric treatment for severe mental illness. The second-
ary research question is whether the intervention
improves treatment motivation, psychosocial functioning
(health and functioning in several life domains) and
quality of life. Thirdly, three theories of motivation will
be assessed on their core theoretical constructs to inves-
tigate which theoretical constructs and which theory is
best able to predict the outcomes in this patient popula-
tion. The identification of possible mediating and mod-
erating mechanisms through which changes in the
outcomes occur, offer a tool for the development of fu-
ture interventions. The study has several strengths and
limitations.
Limitations
The main limitation of the design is that patients and
clinicians are not blind for the treatment condition to
which they are randomized. Clinicians will be informed
about their treatment condition, since it is required that
clinicians in the motivation feedback condition receive
training. Patients are blind for treatment condition at
the baseline assessment, but not at follow-up assessment
since they will realize what condition they are in once
their clinician starts asking them to fill in the feedback
questionnaires monthly after baseline assessment – or
not. This could lead to information bias, as patients
and clinicians in the intervention group may be moreactively involved in the treatment as they expect it
to work, which may enhance the effect of the interven-
tion we find. This would especially be the case for the
subjective (i.e. self-report) outcome measures that are
administered to patients and clinicians, but less so for
the objective outcome measures (e.g. number of no
shows and drop-out as registered by the institution’s
administrative system). Regarding the HoNOS, which is
administered by the patient’s case-manager and an inde-
pendent research assistant, we have weighed the possible
bias that could occur due to the presence of the case-
manager with the advantage of achieving higher re-
sponse rates for the study, thereby minimising a possible
selection bias (that would occur if the more severe men-
tally ill group would decline participation if asked by an
unfamiliar person). We believe that the presence of the
independent research assistant during the administration
and scoring of the HoNOS ensures that the HoNOS is
scored appropriately and will minimise the former bias.
A second limitation is that it is not possible to deter-
mine which exact component of motivation feedback
contributed to the effect, since it might be possible that
measuring patient progress systematically in itself is key
to the effects – whether you measure the patient’s mo-
tivation or the patient’s symptoms or any other patient
characteristic – or the fact that the intervention includes
reminders to the clinician to keep in contact with the
patient for the measurement of the motivation. In order
to have some idea of which elements contributed to the
effect of the intervention, we will monitor the number of
times the feedback was used, the amount of time that
was spent on discussing the feedback, characteristics of
clinicians using the feedback and the motivation of the
clinician to treat the patient. Thirdly, the DSM-IV diag-
nosis is not established with structured diagnostic inter-
views, but is obtained from the patients’ medical
records. This choice was made to reduce patient burden,
since structured interviews were considered too exten-
sive and time-consuming in combination with the other
instruments used in this study.
Strengths
The strengths of this study include the design and the
clinical relevance. The patients in the study are retrieved
from a general population of severe mental illness (i.e.
psychotic disorders and personality disorders), repre-
senting a ‘real-life’ population including patients with a
variety of comorbid disorders rather than a more narrow
selection of patients. Therefore we will be able to
generalize our findings to a large group of outpatients
with psychotic disorders and personality disorders. The
design of the motivation feedback intervention is based
upon empirical evidence of interventions that have
proven efficacious in lowering treatment non-completion
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have been based upon self-report measures from the per-
spective of the patients. The current study also incorpo-
rates the clinicians’ perspective upon the patients’
motivation for treatment. Also, past research concerning
the effects of feedback has largely included patients with
relatively mild problems and non-specific disorders (for
example, the studies by Lambert et al. [13,14] were based
on data from a university outpatient clinic). The current
study will focus upon patients with severe psychiatric
problems.
Regarding the theory comparisons it should be noted
that SDT will be tested most rigorously in this study,
since this theory will be used as the basis for the inter-
vention in this study and its core theoretical compo-
nents will be manipulated (i.e. the basic psychological
needs will be supported by clinicians, and motivational
types will be known and responded to by clinicians).
Although the other two theories are not tested so rigor-
ously (i.e. they are not part of the intervention), the core
theoretical constructs of IM and TTM are followed pro-
spectively over the course of 12 months in order to de-
termine if the constructs behave as the theories suggest
and to see if they are able to predict treatment motiv-
ation and treatment engagement at follow-up. The de-
sign of our study fulfils most of the criteria that have
been suggested by Noar and Zimmerman [81] for theory
comparison studies. The criteria are: 1) having a longitu-
dinal design, 2) using Structural Equation Modelling, 3)
including past behaviour and (4) demographics in the
model tests, 5) including non-college participants in the
sample, 6) having a strong sample size (N>200), 7) utiliz-
ing multiple samples in model testing, 8) utilizing sam-
ples from more than one country, 9) having more than
one dependent variable (e.g. motivation and behaviour),
10) examining more than one behaviour, 11) comparing
more than two theories and (12) empirically examining
an integrated model [81]. All criteria except 8 and 10 are
fulfilled by our design. Furthermore, most previous stud-
ies employing the TransTheoretical Model have only
measured the stages of change, while the model also
incorporates other constructs. The current study mea-
sures both the stages of change, the processes of change,
self-efficacy and the decisional balance constructs. Thus,
a strong aspect of this study is that it includes all core
theoretical constructs of the three motivational theories.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ECJ wrote this manuscript and is the principal investigator of this study. ECJ,
CLM, AD and HJD designed the study. CLM leads the project and CFC, AD,
HJD and SCMS supervise the project. HJD is the statistical advisor of the
project. CLM, CFC, AD and HJD helped to draft the manuscript and provided
comments. WS is a contributing researcher in this study and will focusspecifically on the medication adherence in patients with a psychotic
disorder. SCMS is also a contributing researcher in this study and will focus
upon the level of agreement between clinicians and patients regarding their
motivation for treatment. All authors read and approved the final
manuscript.
Acknowledgements
The authors would like to acknowledge the contributions of the members of
the Epidemiological and Social Psychiatric Research institute, as they have
provided relevant comments and suggestions on earlier drafts of this
manuscript and the design of the study. The current study is funded by the
Mental Health Center West North Brabant (MHC WNB) in collaboration with
the Epidemiological and Social Psychiatric Research institute. As
representative of the funder, AD is involved with the design of the study
and writing of manuscripts concerning the study. However, the data
collection, analyses and interpretation of data will be performed
independently from the funder, under responsibility of the principal
investigator (ECJ). The Mental Health Center Breburg (MHC Breburg)
contributes time, energy and resources to the study for the inclusion of
patients, the execution of the motivation feedback intervention by the
clinicians and the research participation of WS, but is otherwise not a funder
of the study.
Author details
1Department of Psychiatry, Epidemiological and Social Psychiatric Research
institute, Erasmus University Medical Centre, Dr. Molewaterplein 50,
Rotterdam 3015 GE, The Netherlands. 2GGZ Westelijk Noord Brabant, Post
Office Box 371, Bergen op Zoom 4600 AJ, The Netherlands. 32e De
Carpentierstraat 232, The Hague 2595 HN, The Netherlands. 4GGZ Breburg,
Post Office Box 770, Tilburg 5000 AT, The Netherlands. 5Faculty of Social
Sciences, Tilburg University, Post Office Box 90153, Tilburg 5000 LE, The
Netherlands. 6Netherlands Institute of Mental Health and Addiction (Trimbos
Institute), PO Box 725, Utrecht 3500 AS, The Netherlands.
Received: 28 February 2012 Accepted: 21 November 2012
Published: 24 November 2012
References
1. Torrey EF, Zdanowicz M: Outpatient commitment: what, why and for
whom. Psychiatr Serv 2001, 52:337–341.
2. Delaney C: Reducing recidivism: medication versus psychosocial
rehabilitation. J Psychosoc Nurs Ment Health Serv 1998, 36:28–34.
3. Lehner RK, Dopke CA, Cohen K, Edstrom K, Maslar M, Slagg NB, Yohanna D:
Outpatient treatment adherence and serious mental illness: a review of
interventions. Am J Psychiatr Rehabil 2007, 10:245–274.
4. Staring ABP, Mulder CL, Van der Gaag M, Selten JP, Lonnen AJM,
Hengeveld MW: Understanding and improving treatment adherence in
patients with psychotic disorders: a review and proposed intervention.
Current Psychiatry Reviews 2006, 2:487–494.
5. Clayton CD, Veach J, Macfadden W, Haskins J, Docherty JP, Lindenmayer JP:
Assessment of clinician awareness of nonadherence using a new
structured rating scale. J Psychiatr Pract 2010, 16:164–169.
6. McMurran M, Huband N, Overton E: Non-completion of personality
disorder treatments: a systematic review of correlates, consequences,
and interventions. Clin Psychol Rev 2010, 30:277–287.
7. Barrett MS, Chua WJ, Crits-Christoph P, Gibbons MB, Casiano D,
Thompson D: Early withdrawal from mental health treatment:
implications for psychotherapy practice. Psychotherapy 2008, 45:247–267.
8. Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R,
Docherty JP: Assessment of adherence problems in patients with serious
and persistent mental illness: recommendations from the expert
consensus guidelines. J Psychiatr Pract 2010, 16:34–45.
9. Centorrino F, Hernan MA, Drago-Ferrante G, Rendall M, Apicella A, Langar G,
Baldessarini RJ: Factors associated with noncompliance with psychiatric
outpatient visits. Psychiatr Serv 2001, 52:378–380.
10. Ryan RM, Plant RW, O’Malley S: Initial motivations for alcohol treatment:
relations with patient characteristics, treatment involvement, and
dropout. Addict Behav 1995, 20:279–297.
11. Mulder CL, Koopmans GT, Hengeveld MW: Lack of motivation for
treatment in emergency psychiatry patients. Soc Psychiatry Psychiatr
Epidemiol 2005, 40:484–488.
Jochems et al. BMC Psychiatry 2012, 12:209 Page 16 of 17
http://www.biomedcentral.com/1471-244X/12/20912. Drieschner KH, Lammers SMM, van der Staak CPF: Treatment motivation:
an attempt for clarification of an ambiguous concept. Clin Psychol Rev
2004, 23:1115–1137.
13. Lambert MJ, Whipple JL, Smart DW, Vermeersch DA, Nielsen SL: The effects
of providing therapists with feedback on patient progress during
psychotherapy: Are outcomes enhanced? Psychother Res 2001,
11:49–68.
14. Lambert MJ, Whipple JL, Vermeersch DA, Smart DW, Hawkins EJ, Nielsen SL,
Goates M: Enhancing psychotherapy outcomes via providing feedback
on client progress: a replication. Clin Psychol Psychother 2002, 9:91–103.
15. Lambert MJ, Whipple JL, Hawkins EJ: Is it time for clinicians to routinely
track patient outcome? a meta-analysis. Clin Psychol Sci Pract 2003,
10:288–301.
16. Whipple JL, Lambert MJ, Vermeersch DA, Smart DW, Nielsen SL, Hawkins EJ:
Improving the effects of psychotherapy: the use of early identification of
treatment failure and problem-solving strategies in routine practice.
J Couns Psychol 2003, 50:59–68.
17. Lambert MJ, Harmon C, Slade K, Whipple JL, Hawkins EJ: Providing
feedback to psychotherapists on their patients' progress: clinical results
and practice suggestions. J Clin Psychol 2005, 61:165–174.
18. Hawkins EJ, Lambert MJ, Vermeersch DA, Slade KL, Tuttle KC: The
therapeutic effects of providing patient progress information to
therapists and patients. Psychother Res 2004, 14:308–327.
19. Sapyta J, Riemer M, Bickman L: Feedback to clinicians: theory, research,
and practice. J Clin Psychol 2005, 61:145–153.
20. Priebe S, McCabe R, Bullenkamp J, Hansson L, Lauber C, Martinez-Leal R,
Rossler W, Salize H, Svensson B, Torres-Gonzales F, et al: Structured
patient-clinician communication and 1-year outcome in community
mental healthcare: cluster randomised controlled trial. Br J Psychiatry
2007, 191:420–426.
21. Marshall M, Lockwood A, Green G, Zajac-Roles G, Roberts C, Harrison G:
Systematic assessments of need and care planning in severe mental
illness: cluster randomised controlled trial. Br J Psychiatry 2004,
185:163–168.
22. Drukker M, van Os J, Bak M, a Campo J, Delespaul P: Systematic
monitoring of needs for care and global outcomes in patients with
severe mental illness. BMC Psychiatry 2010, 10:36.
23. Monti PM, Barnett NP, Colby SM, Gwaltney CJ, Spirito A, Rohsenow DJ,
Woolard R: Motivational interviewing versus feedback only in emergency
care for young adult problem drinking. Addiction 2007, 102:1234–1243.
24. Vader AM, Walters ST, Prabhu GC, Houck JM, Field CA: The language of
motivational interviewing and feedback: counselor language, client
language, and client drinking outcomes. Psychol Addict Behav 2010,
24:190–197.
25. Walters ST, Vader AM, Harris RT, Field CA, Jouriles EN: Dismantling
motivational interviewing and feedback for college drinkers: a
randomized clinical trial. J Consult Clin Psychol 2009, 77:64–73.
26. Deci EL, Ryan RM: The "what" and "why" of goal pursuits: human needs
and the self-determination of behavior. Psychological Inquiry: An
International Journal for the Advancement of Psychological Theory 2000,
11:227–268.
27. Deci EL, Eghrari H, Patrick BC, Leone DR: Facilitating internalization: the
self-determination theory perspective. J Pers 1994, 62:119–142.
28. Prochaska JO, DiClemente CC: Stages and processes of self-change in
smoking: toward an integrative model of change. J Consult Clin Psychol
1983, 5:390–395.
29. Jochems EC, Mulder CL, van Dam A, Duivenvoorden HJ: A critical analysis
of the utility and compatibility of motivation theories in psychiatric
treatment. Current Psychiatry Reviews 2011, 7:298–312.
30. Deci EL, Ryan RM: Self-determination theory: a macrotheory of human
motivation, development, and health. Can Psychol 2008, 49:182–185.
31. Ryan RM, Deci EL: A self-determination theory approach to
psychotherapy: the motivational basis for effective change. Can Psychol
2008, 49:186–193.
32. Drake RE, Goldman HE, Leff H, Lehman AF, Dixon L, Mueser KT, Torrey WC:
Implementing evidence-based practices in routine mental health service
settings. Psychiatr Serv 2001, 52:179–182.
33. van Veldhuizen JR: FACT: a Dutch version of ACT. Community Ment Health
J 2007, 43:421–433.
34. Bachrach LL: Defining chronic mental illness: a concept paper. Hosp
Community Psychiatry 1988, 39:383–388.35. Ruggeri M, Leese M, Thornicroft G, Bisoffi G, Tansella M: Definition and
prevalence of severe and persistent mental illness. Br J Psychiatry 2000,
177:149–155.
36. Kortrijk HE, Staring AB, van Baars AW, Mulder CL: Involuntary admission
may support treatment outcome and motivation in patients receiving
assertive community treatment. Soc Psychiatry Psychiatr Epidemiol 2010,
45:245–252. Epub 2009 May 2002.
37. Prochaska JO, DiClemente CC, Norcross JC: In search of how people
change: applications to addictive behaviors. J Addict Nurs 1992,
5:2–16.
38. Drieschner KH: Measuring treatment motivation and treatment engagement
in forensic psychiatric outpatient treatment: development of two instruments.
Enschede: Febodruk; 2005.
39. Tait L, Birchwood M, Trower P: A new scale (SES) to measure engagement
with community mental health services. J Ment Health 2002, 11:191–198.
40. Morisky DE, Ang A, Krousel-Wood M, Ward HJ: Predictive validity of a
medication adherence measure in an outpatient setting. J Clin Hypertens
(Greenwich) 2008, 10:348–354.
41. Wild T, Cunningham JA, Ryan RM: Social pressure, coercion, and client
engagement at treatment entry: a self-determination theory perspective.
Addict Behav 2006, 31:1858–1872.
42. Williams GC, Grow VM, Freedman ZR, Ryan RM, Deci EL: Motivational
predictors of weight-loss and weight-loss maintenance. J Pers Soc Psychol
1996, 70:115–126.
43. Williams GC, Cox EM, Kouides R, Deci EL: Presenting the facts about
smoking to adolescents: effects of an autonomy-supportive style. Arch
Pediatr Adolesc Med 1999, 153:959–964.
44. Hodgins D: Stages of change assessments in alcohol problems:
agreement across self- and clinician-reports. Subst Abus 2001, 22:87–96.
45. Wright JA, Velicer WF, Prochaska JO: Testing the predictive power of the
transtheoretical model of behavior change applied to dietary fat intake.
Health Educ Res 2009, 24:224–236.
46. Sutton S: Back to the drawing board? a review of applications of the
transtheoretical model to substance use. Addiction 2001, 96:175–186.
47. McConnaughy EA, Prochaska JO, Velices WF: Stages of change in
psychotherapy: measurement and sample profiles. Psychotherapy: Theory,
Research and Practice 1983, 20:368–375.
48. Jonge JM, Schaap CPDR, Schippers GM: Motivatie voor verandering: een
Nederlandse versie van de University of Rhode Island Change
Assessment (URICA-NL). Diagnostiek-wijzer 2002, 5:114–122.
49. Hoeppner BB, Velicer WF, Redding CA, Rossi JS, Prochaska JO, Pallonen UE,
Meier KS: Psychometric evaluation of the smoking cessation processes of
change scale in an adolescent sample. Addict Behav 2006, 31:1363–1372.
50. Prochaska JO, Velicer WF, DiClemente CC, Fava JL: Measuring processes of
change: applications to the cessation of smoking. J Consult Clin Psychol
1988, 56:520–528.
51. Rossi SR, Rossi JS, Rossi-DelPrete LM, Prochaska JO, Banspach SW,
Carleton RA: A processes of change model for weight control for
participants in community-based weight loss programs. Int J Addict 1994,
29:161–177.
52. Nidecker M, DiClemente CC, Bennett ME, Bellack AS: Application of the
Transtheoretical Model of change: psychometric properties of leading
measures in patients with co-occurring drug abuse and severe mental
illness. Addict Behav 2008, 33:1021–1030.
53. Drieschner KH, Boomsma A: The treatment motivation scales for forensic
outpatient treatment (TMS-F): construction and psychometric evaluation.
Assessment 2008, 15:224–241.
54. Drieschner KH, Boomsma A: Validation of the treatment motivation scales
for forensic outpatient treatment (TMS-F). Assessment 2008, 15:242–255.
55. Drieschner KH, Boomsma A: The treatment engagement rating scale (TER)
for forensic outpatient treatment: description, psychometric properties,
and norms. Psychology, Crime & Law 2008, 14:299–315.
56. Mulder CL, Staring ABP, Loos J, Buwalda VJA, Kuijpers S, Sytema S,
Wierdsma AI: De health of the nation outcome scales (honos) als
instrument voor ‘routine outcome assessment’. Tijdschr Psychiatr 2004,
46:273–284.
57. Wing JK, Beevor AS, Curtis RH, Park SB, Hadden S, Burns A: Health of
the nation outcome scales (HoNOS). Research and development.
Br J Psychiatr 1998, 172:11–18.
58. Overall JE, Gorham DR: The brief psychiatric rating scale. Psychol Rep 1962,
10:799–812.
Jochems et al. BMC Psychiatry 2012, 12:209 Page 17 of 17
http://www.biomedcentral.com/1471-244X/12/20959. Andersen J, Larsen J, Schultz V, Nielsen BM, et al: The brief psychiatric
rating scale: dimension of schizophrenia: reliability and construct
validity. Psychopathology 1989, 22:168–176.
60. Priebe S, Huxley P, Knight S, Evans S: Application and results of the
manchester short assessment of quality of life (MANSA). Int J Soc
Psychiatry 1999, 45:7–12.
61. Bjorkman T, Svensson B: Quality of life in people with severe mental
illness. Reliability and validity of the Manchester short assessment of
quality of life (MANSA). Nord J Psychiatry 2005, 59:302–306.
62. McFarland J, McDonald C, Hallahan B: Insight in mental illness: an
educational review. Ir J Psychol Med 2009, 26:32–36.
63. Birchwood M, Smith J, Drury V, Healy J, Macmillan F, Slade M: A self-report
Insight Scale for psychosis: reliability, validity and sensitivity to change.
Acta Psychiatr Scand 1994, 89:62–67.
64. Stefanopoulou E, Manoharan A, Landau S, Geddes JR, Goodwin G, Frangou
S: Cognitive functioning in patients with affective disorders and
schizophrenia: a meta-analysis. Int Rev Psychiatry 2009, 21:336–356.
65. Quee PJ, van der Meer L, Bruggeman R, de Haan L, Krabbendam L, Cahn W,
Mulder NC, Wiersma D, Aleman A: Insight in psychosis: relationship with
neurocognition, social cognition and clinical symptoms depends on
phase of illness. Schizophr Bull 2011, 37:29–37.
66. Aleman A, Agrawal N, Morgan KD, David AS: Insight in psychosis and
neuropsychological function: meta-analysis. Br J Psychiatry 2006,
189:204–212.
67. Grant DA, Berg EA: A behavioral analysis of degree of reinforcement and
ease of shifting to new responses in a Weigl-type card-sorting problem.
J Exp Psychol 1948, 38:404–411.
68. Wilson BA, Evans JJ, Alderman N, Burgess PW, Emslie H: Behavioural
assessment of the dysexecutive syndrome. In Methodology of frontal and
executive function. Edited by Rabbitt P. Hove: Psychology Press;
1997:239–250.
69. Wilson BA, Evans JJ, Emslie H, Alderman N, Burgess PW: The development
of an ecologically valid test for assessing patients with a dysexecutive
syndrome. Neuropsychol Rehabil 1998, 8:213–228.
70. Jelicic M, Henquest CEC, Derix MMA, Jolles J: Test-retest stability of the
behavioural assessment of dysexecutive syndrome in a sample of
psychiatric patients. Int J Neurosci 2001, 110:73–78.
71. De Weert-Van Oene GH, De Jong CA, Jorg F, Schrijvers GJ: The helping
alliance questionnaire: psychometric properties in patients with
substance dependence. Subst Use Misuse 1999, 34:1549–1569.
72. Sa P, Ma R, Mb C, Oc A, Ra MC: Does the therapeutic relationship predict
outcomes of psychiatric treatment in patients with psychosis? A
Systematic Review. Psychother Psychosom 2011, 80:70–77.
73. Calsyn RJ, Klinkenberg WD, Morse GA, Lemming MR: Predictors of the
working alliance in assertive community treatment. Community Ment
Health J 2006, 42:161–175.
74. Link BG, Struening EL, Neese-Todd S, Asmussen S, Phelan JC: On describing
and seeking to change the experience of stigma. Psychiatr Rehabil Skills
2002, 6:201–231.
75. Staring AB, Van der Gaag M, Van den Berge M, Duivenvoorden HJ,
Mulder CL: Stigma moderates the associations of insight with depressed
mood, low self-esteem, and low quality of life in patients with
schizophrenia spectrum disorders. Schizophr Res 2009, 115:363–369.
76. Link B, Castille DM, Stuber J, Link B, Castille DM, Stuber J: Stigma and
coercion in the context of outpatient treatment for people with mental
illnesses. Soc Sci Med 2008, 67:409–419.
77. Howard MO, Kivlahan D, Walker RD: Cloninger's tridimensional theory of
personality and psychopathology: applications to substance use
disorders. J Stud Alcohol 1997, 58:48–66.
78. Duijsens IJ, Spinhoven P, Goekoop JG, Spermon T, Eurelings-Bontekoe EH:
The Dutch temperament and character inventory (TCI): dimensional
structure, reliability and validity in a normal and psychiatric outpatient
sample. Personal Individ Differ 2000, 28:487–499.
79. Cloninger CR, Svrakic DM, Przybeck TR: A psychobiological model
of temperament and character. Arch Gen Psychiatry 1993,
50:975–990.80. Staring AB, Van der Gaag M, Koopmans GT, Selten JP, Van Beveren JM,
Hengeveld MW, Loonen AJ, Mulder CL: Treatment adherence therapy in
people with psychotic disorders: randomised controlled trial. Br J
Psychiatry 2010, 197:448–455.
81. Noar SM, Zimmerman RS: Health behavior theory and cumulative
knowledge regarding health behaviors: are we moving in the right
direction? Health Educ Res 2005, 20:275–290.
doi:10.1186/1471-244X-12-209
Cite this article as: Jochems et al.: Motivation and treatment
engagement intervention trial (MotivaTe-IT): the effects of motivation
feedback to clinicians on treatment engagement in patients with severe
mental illness. BMC Psychiatry 2012 12:209.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
